Cover Image
Market Research Report

ADC Contract Manufacturing Market (3rd Edition), 2018-2030

Published by ROOTS ANALYSIS Product code 295020
Published Content info 350 Pages
Delivery time: 1-2 business days
Price
Back to Top
ADC Contract Manufacturing Market (3rd Edition), 2018-2030
Published: September 11, 2018 Content info: 350 Pages
Description

Antibody drug conjugates (ADCs) are one of the most popular classes of targeted therapeutic agents and have captured the attention of both large and small pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the cytotoxic potential of a chemotherapy drug; such conjugates are believed to be more efficient and effective in specifically identifying and eliminating cells / pathogens that are associated with disease(s). Since the approval of first ADC (MYLOTARG™) in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. Presently, there are four approved ADCs in the market: BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011). In fact, in the last 4-5 years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. This is justified by the fact that currently there are close to 200 unique ADC product candidates in the clinical / preclinical phase of development.

Owing to the fact that these novel conjugates are highly potent toxic molecules, their manufacturing requires elaborate technical capabilities, along with the required expertise and manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads that are used in ADCs requires specialized manufacturing facilities and equipment, highly contained production environments and experts in advanced synthetic chemistry and purification techniques. In addition, ADC developers require access to state-of-art linker technologies and must possess the ability to carry out the bioconjugation of the antibody to the cytotoxic drug. Due to the aforementioned challenges, stakeholders generally don't opt for manufacturing ADCs in-house. In fact, some of the leading players in this domain are dependent on contract manufacturers for the supply of one or more components of their ADC product candidates. Although some big pharma companies carry out in-house manufacturing of their ADC products, the trend of outsourcing such operations is likely to flourish in the coming years. This trend is expected to be driven by the several small companies and start-ups that are presently involved in development of ADCs.

Synopsis:

The “ADC Contract Manufacturing Market (3rd edition), 2018-2030” report offers a comprehensive study of the current scenario and future potential of the contract manufacturing market for ADCs. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current status of the market with respect to the players involved in the manufacturing of ADCs. It features information on headquarters, size of the company, the types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operations, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / anaytical development).
  • Elaborate profiles of the contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A comparative analysis of the key contract manufacturers based onvarious parameters, including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services.
  • An analysis of the recent investments (since 2012) made in this domain, the proceeds of which were intended to be used for the expansion or establishment of new facilities dedicated to offering ADC related services.
  • An analysis of the recent collaborations (since 2012) focused on manufacturing of ADCs on the basis of year in which the agreement was signed, type of agreement, key players and the geographical distribution of this activity.
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract service providers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).
  • An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.
  • A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
  • A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).
  • An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody manufacturing, HPAPI / cytotoxic production, conjugation / linker and fill / finish), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with following stakeholders:

  • Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • John Burt (Chief Executive Officer, Abzena)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the period 2018-2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the ADC contract manufacturing marketin the mid to long term.

Chapter 3 is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

Chapter 4 provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on headquarters, size of the company, types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operation, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / analytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic drug manufacturers along with the information on location of facilities dedicated to the manufacturing of such components.

Chapter 5 features profiles of contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

Chapter 6 features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services. The results of this analysis were used to highlight the features of the most competent companies working in this domain.

Chapter 7 highlightstheinvestments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on month / year of the development, type of development, amount invested (if available), focus area (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial) and location of the facility in which the investment was made.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market. We have also discussed the different partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions / mergers) and the most common forms of deals / agreements that have been established between 2012-H1 2018. It consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of ADCs. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 features a comprehensive analysis of the overall installed manufacturing / bioconjugation capacity of contract service providers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).

Chapter 10 provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.

Chapter 11 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.

Chapter 12 features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).

Chapter 13 features acomprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody, cytotoxic / linker, conjugation, fill / finish and others), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO)

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents
Product Code: RA100117

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Essential Components of ADCs
    • 3.2.1 Antibody
    • 3.2.2. Cytotoxin
    • 3.2.3. Linker
  • 3.3. ADC Manufacturing
    • 3.3.1. Key Steps
    • 3.3.2. Technical Challenges
    • 3.3.3. Growing Trend of Contract Manufacturing
  • 3.4. Challenges Associated with Supply Chain and Method Transfer
    • 3.4.1. Growing Demand for One Stop Shops and Integrated Service Providers
  • 3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. ADC Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Distribution by Location of Headquarters
    • 4.2.2. Distribution by Year of Establishment
    • 4.2.3. Distribution by Company Size
    • 4.2.4. Distribution by Service(s) Offered
    • 4.2.5. Distribution by Location of Manufacturing Facility
    • 4.2.6. Distribution by Scale of Operation
    • 4.2.7. Distribution by Other ADC Services Offered
  • 4.3. Antibody Manufacturing Service Providers
  • 4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Abzena
    • 5.2.1. Company Overview and Financial Information
    • 5.2.2. ADC Offerings
    • 5.2.3. Manufacturing Facilities
    • 5.2.4. Recent Developments
    • 5.2.5. Future Outlook
  • 5.3. Ajinomoto Althea
    • 5.3.1. Company Overview and Financial Information
    • 5.3.2. ADC Offerings
    • 5.3.3. Manufacturing Facilities
    • 5.3.4. Recent Developments
    • 5.3.5. Future Outlook
  • 5.4. BSP Pharmaceuticals
    • 5.4.1. Company Overview and Financial Information
    • 5.4.2. ADC Offerings
    • 5.4.3. Manufacturing Facilities
    • 5.4.4. Recent Developments
    • 5.4.5. Future Outlook
  • 5.5. CARBOGEN AMCIS
    • 5.5.1. Company Overview and Financial Information
    • 5.5.2. ADC Offerings
    • 5.5.3. Manufacturing Facilities
    • 5.5.4. Recent Developments
    • 5.5.5. Future Outlook
  • 5.6. Catalent Pharma Solutions
    • 5.6.1. Company Overview and Financial Information
    • 5.6.2. ADC Offerings
    • 5.6.3. Manufacturing Facilities
    • 5.6.4. Recent Developments
    • 5.6.5. Future Outlook
  • 5.7. Cerbios-Pharma
    • 5.7.1. Company Overview and Financial Information
    • 5.7.2. ADC Offerings
    • 5.7.3. Manufacturing Facilities
    • 5.7.4. Recent Developments
    • 5.7.5. Future Outlook
  • 5.8. Creative Biolabs
    • 5.8.1. Company Overview and Financial Information
    • 5.8.2. ADC Offerings
    • 5.8.3. Manufacturing Facilities
    • 5.8.4. Recent Developments
    • 5.8.5. Future Outlook
  • 5.9. Goodwin Biotechnology
    • 5.9.1. Company Overview and Financial Information
    • 5.9.2. ADC Offerings
    • 5.9.3. Manufacturing Facilities
    • 5.9.4. Recent Developments
    • 5.9.5. Future Outlook
  • 5.10. Levena Biopharma
    • 5.10.1. Company Overview and Financial Information
    • 5.10.2. ADC Offerings
    • 5.10.3. Manufacturing Facilities
    • 5.10.4. Recent Developments
    • 5.10.5. Future Outlook
  • 5.11. Lonza
    • 5.11.1. Company Overview and Financial Information
    • 5.11.2. ADC Offerings
    • 5.11.3. Manufacturing Facilities
    • 5.11.4. Recent Developments
    • 5.11.5. Future Outlook
  • 5.12. MabPlex
    • 5.12.1. Company Overview and Financial Information
    • 5.12.2. ADC Offerings
    • 5.12.3. Manufacturing Facilities
    • 5.12.4. Recent Developments
    • 5.12.5. Future Outlook
  • 5.13. Merck (SAFC)
    • 5.13.1. Company Overview and Financial Information
    • 5.13.2. ADC Offerings
    • 5.13.3. Manufacturing Facilities
    • 5.13.4. Recent Developments
    • 5.13.5. Future Outlook
  • 5.14. Novasep
    • 5.14.1. Company Overview and Financial Information
    • 5.14.2. ADC Offerings
    • 5.14.3. Manufacturing Facilities
    • 5.14.4. Recent Developments
    • 5.14.5. Future Outlook
  • 5.15. Pierre Fabre
    • 5.15.1. Company Overview and Financial Information
    • 5.15.2. ADC Offerings
    • 5.15.3. Manufacturing Facilities
    • 5.15.4. Recent Developments
    • 5.15.5. Future Outlook
  • 5.16. Piramal Pharma Solutions
    • 5.16.1. Company Overview and Financial Information
    • 5.16.2. ADC Offerings
    • 5.16.3. Manufacturing Facilities
    • 5.16.4. Recent Developments
    • 5.16.5. Future Outlook
  • 5.17. Syngene
    • 5.17.1. Company Overview and Financial Information
    • 5.17.2. ADC Offerings
    • 5.17.3. Manufacturing Facilities
    • 5.17.4. Recent Developments
    • 5.17.5. Future Outlook
  • 5.18. WuXi Biologics
    • 5.18.1. Company Overview and Financial Information
    • 5.18.2. ADC Offerings
    • 5.18.3. Manufacturing Facilities
    • 5.18.4. Recent Developments
    • 5.18.5. Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Methodology
    • 6.2.1. Assumptions and Parameters Evaluated
  • 6.3. Affiliated Insights
    • 6.3.1. Spider Web Competitive Analysis: Cambrex
    • 6.3.2. Spider Web Competitive Analysis: Cerbios-Pharma
    • 6.3.3. Spider Web Competitive Analysis: Merck (SAFC)
    • 6.3.4. Spider Web Competitive Analysis: Novasep
    • 6.3.5. Spider Web Competitive Analysis: Pierre Fabre
    • 6.3.6. Spider Web Competitive Analysis: Piramal Pharma Solutions
    • 6.3.7. Spider Web Competitive Analysis: WuXi Biologics

7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS

  • 7.1. Chapter Overview
  • 7.2. ADC Contract Manufacturers: Recent Facility Expansions
    • 7.2.1. Analysis by Year of Expansion
    • 7.2.2. Analysis by Type of Expansion
    • 7.2.3. Analysis by Type of Service Offered
    • 7.2.4. Analysis by Type of Service and Year of Expansion
    • 7.2.5. Analysis by Scale of Operation
    • 7.2.6. Analysis by Location of Facility
    • 7.2.7. Analysis by Scale of Operation and Location of Facility
    • 7.2.8. Analysis by Key Players and Type of Expansion

8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Key Players by Number of Partnerships
    • 8.3.4. Regional Analysis
      • 8.3.4.1. Most Active Players
      • 8.3.4.2. Intercontinental and Intracontinental Agreements

9. ADC MANUFACTURING: CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. ADC Manufacturing: Overall Installed Global Capacity
  • 9.3.1. Distribution by Size of Manufacturers
    • 9.3.2. Distribution by Key Players
    • 9.3.3. Distribution by Headquarters of Manufacturers
    • 9.3.4. Distribution by Location of Manufacturing Facilities
      • 9.3.4.1 By Country
      • 9.3.4.2. By Continent

10. ADC THERAPEUTICS: MARKET OVERVIEW

  • 10.1. Chapter Overview
  • 10.2. ADC Therapeutics: Clinical Pipeline
    • 10.2.1. Distribution by Phase of Development
    • 10.2.2. Distribution by Indication
    • 10.2.3. Distribution by Linker Type
    • 10.2.4. Distribution by Payload Type
    • 10.2.5. Distribution of Technology Providers by Number of Molecules
  • 10.3. ADC Therapeutics: Preclinical / Discovery Pipeline
    • 10.3.1. Distribution of Leading Players by Number of Molecules

11. ADC CONJUGATION TECHNOLOGY PLATFORMS

  • 11.1. Chapter Overview
  • 11.2. First Generation ADC Technologies
  • 11.3. Second Generation ADC Technologies
    • 11.3.1. Cysteine and Selenocysteine Engineering
    • 11.3.2. Unnatural Amino Acid Engineering
    • 11.3.3. Amino-Terminal Serine Engineering
  • 11.4. Third Generation ADC Technologies
    • 11.4.1. Enzyme-Assisted Ligation Approaches
    • 11.4.2. Glycan Remodeling Approaches
    • 11.4.3. Ligation at Fab Nucleotide-Binding Site
    • 11.4.4. Cysteine Rebridging
    • 11.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
  • 11.5. Evolutionary Analysis

12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. ADC Therapeutics: Overall Clinical Trial Analysis
    • 12.3.1. Analysis by Trial Registration Year
    • 12.3.2. Geographical Analysis by Number of Clinical Trials
    • 12.3.3. Geographical Analysis by Enrolled Patient Population
  • 12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
    • 12.4.1. Auristatin based Molecules
      • 12.4.1.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.1.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.1.3. Analysis by Duration of Clinical Trials
    • 12.4.2. Maytansinoid based Molecules
      • 12.4.2.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.2.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.2.3. Analysis by Duration of Clinical Trials
    • 12.4.3. Calicheamicin based Molecules
      • 12.4.3.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.3.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.3.3. Analysis by Duration of Clinical Trials
    • 12.4.4. PBDs (talirine, tesirine) based Molecules
      • 12.4.4.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.4.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.4.3. Analysis by Duration of Clinical Trials
    • 12.4.5. Duocarmycin based Molecules
      • 12.4.5.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.5.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.5.3. Analysis by Duration of Clinical Trials
    • 12.4.6. DXd (exatecan Derivative) based Molecules
      • 12.4.6.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.6.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.6.3. Analysis by Duration of Clinical Trials
    • 12.4.7. Molecules having Other Types of Payloads
      • 12.4.7.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.4.7.2. Geographical Analysis by Enrolled Patient Population
      • 12.4.7.3. Analysis by Duration of Clinical Trials
  • 12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type
    • 12.5.1. VC based Molecules
      • 12.5.1.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.1.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.1.3. Analysis by Duration of Clinical Trials
    • 12.5.2. Hydrazone Linker based Molecules
      • 12.5.2.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.2.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.2.3. Analysis by Duration of Clinical Trials
    • 12.5.3. SMCC based Molecules
      • 12.5.3.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.3.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.3.3. Analysis by Duration of Clinical Trials
    • 12.5.4. VA based Molecules
      • 12.5.4.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.4.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.4.3. Analysis by Duration of Clinical Trials
    • 12.5.5. SPDB based Molecules
      • 12.5.5.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.5.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.5.3. Analysis by Duration of Clinical Trials
    • 12.5.6. Molecules having Other Types of Linkers
      • 12.5.6.1. Geographical Analysis by Trial Phase and Recruitment Status
      • 12.5.6.2. Geographical Analysis by Enrolled Patient Population
      • 12.5.6.3. Analysis by Duration of Clinical Trials

13. ADC THERAPEUTICS: DEMAND ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. ADC Therapeutics: Overall Annual Demand
    • 13.3.1. ADC Therapeutics: Annual Commercial Demand
      • 13.3.1.1. Distribution by Payload Type
      • 13.3.1.2. Distribution by Linker Type
      • 13.3.1.3. Distribution by Indication Type
    • 13.3.2. ADC Therapeutics: Annual Clinical Demand
      • 13.3.2.1. Distribution by Phase of Development
      • 13.3.2.2. Distribution by Payload Type
      • 13.3.2.3. Distribution by Linker Type
      • 13.3.2.4. Distribution by Indication Type
      • 13.3.2.5. Distribution by Region
    • 13.3.3. ADC Therapeutics: Demand and Supply Analysis

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology
  • 14.3. Overall ADC Therapeutics Market, 2018-2030
  • 14.4. Input Data and Key Assumptions
  • 14.5. Overall ADC Contract Manufacturing Market, 2018-2030
    • 14.5.1. ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
    • 14.5.2. ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
  • 14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
    • 14.6.1. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Components of ADC
    • 14.6.2. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
    • 14.6.3. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
    • 14.6.4. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type
    • 14.6.5. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
  • 14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030
    • 14.7.1. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC
    • 14.7.2. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
    • 14.7.3. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
    • 14.7.4. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type
    • 14.7.5. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region

15. SWOT ANALYSIS

  • 15.1. Chapter Overview
    • 15.1.1. Strengths
    • 15.1.2. Weaknesses
    • 15.1.3. Opportunities
    • 15.1.4. Threats

16. CONCLUSION

  • 16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
  • 16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
  • 16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
  • 16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies being Centered in the US
  • 16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
  • 16.6. As More Late Stage Candidates Receive Approvals, the Annual Demand for ADC Therapeutics is Anticipated to Increase

17. INTERVIEW TRANSCRIPTS

  • 17.1. Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals
  • 17.2. Anthony DeBoer (Director, Business Development, Synaffix)
  • 17.3. Christian Bailly, Director of CDMO, Pierre Fabre
  • 17.4. Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • 17.5. Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager, Catalent Pharma Solutions
  • 17.6. John Burt (Chief Executive Officer, Abzena)
  • 17.7. Laurent Ducry, Head of Bioconjugates Commercial Development, Lonza
  • 17.8. Mark Wright, Site Head, Piramal Healthcare
  • 17.9. Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • 17.10. Anonymous, Director, Business Development, Leading CMO
  • 17.11. Anonymous, Chief Executive Officer, Leading CMO

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Components of an ADC
  • Figure 3.2: ADC Manufacturing Steps
  • Figure 4.1: ADC Contract Manufacturers: Distribution by Location of Headquarters
  • Figure 4.2: ADC Contract Manufacturers: Distribution by Year of Establishment
  • Figure 4.3: ADC Contract Manufacturers: Distribution by Company Size
  • Figure 4.4: ADC Contract Manufacturers: Distribution by Services Offered
  • Figure 4.5: ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
  • Figure 4.6: ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 4.7: ADC Contract Manufacturers: Distribution by Scale of Operation
  • Figure 4.8: ADC Contract Manufacturers: Distribution based on Other Services Offered
  • Figure 6.1: Company Competitiveness Analysis: Assumptions and Key Parameters
  • Figure 6.2: Company Competitiveness Analysis: Dot-Plot Representation
  • Figure 6.3: Spider-Web Competitive Analysis: Cambrex
  • Figure 6.4: Spider-Web Competitive Analysis: Competitive Cerbios-Pharma
  • Figure 6.5: Spider-Web Competitive Analysis: Merck (SAFC)
  • Figure 6.6: Spider-Web Competitive Analysis: Novasep
  • Figure 6.7: Spider-Web Competitive Analysis: Pierre Fabre
  • Figure 6.8: Spider-Web Competitive Analysis: Piramal Pharma Solutions
  • Figure 6.9: Spider-Web Competitive Analysis: WuXi Biologics
  • Figure 7.1: ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
  • Figure 7.2: ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
  • Figure 7.3: ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
  • Figure 7.4: ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
  • Figure 7.5: ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
  • Figure 7.6: ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
  • Figure 7.7: ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
  • Figure 7.8: ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
  • Figure 8.1: ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
  • Figure 8.2: ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
  • Figure 8.3: ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
  • Figure 8.4: ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
  • Figure 8.5: ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
  • Figure 9.1: Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
  • Figure 9.2: Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
  • Figure 9.3: Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
  • Figure 9.4: Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
  • Figure 9.5: Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
  • Figure 10.1: ADCs Clinical Pipeline: Distribution by Phase of Development
  • Figure 10.2: ADCs Clinical Pipeline: Distribution by Indication
  • Figure 10.3: ADCs Clinical Pipeline: Distribution by Type of Linker
  • Figure 10.4: ADCs Clinical Pipeline: Distribution by Type of Warhead
  • Figure 10.5: ADCs Clinical Pipeline: Distribution by Technology Providers
  • Figure 10.6: ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
  • Figure 11.1: ADC Conjugation Platforms: Technological Evolution
  • Figure 11.2: ADC Conjugation Platforms: Technology Landscape
  • Figure 12.1: ADC Therapeutics: Year-wise Trend of Clinical Trials
  • Figure 12.2: Geographical Clinical Trial Analysis: Distribution by Number of Trials
  • Figure 12.3: Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
  • Figure 12.4: Geographical Clinical Trial Analysis: Distribution by Payload Type
  • Figure 12.5: Geographical Clinical Trial Analysis(Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.6: Geographical Clinical Trial Analysis(Auristatin based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.7: Geographical Clinical Trial Analysis(Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.8: Geographical Clinical Trial Analysis(Maytansinoid based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.9: Geographical Clinical Trial Analysis(Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.10: Geographical Clinical Trial Analysis(Calicheamicin based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.11: Geographical Clinical Trial Analysis(PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.12: Geographical Clinical Trial Analysis(PBDs based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.13: Geographical Clinical Trial Analysis(Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.14: Geographical Clinical Trial Analysis(Duocarmycin based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.15: Geographical Clinical Trial Analysis(DXd based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.16: Geographical Clinical Trial Analysis(DXd based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.17: Geographical Clinical Trial Analysis(Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
  • Figure 12.18: Geographical Clinical Trial Analysis(Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
  • Figure 12.19: ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
  • Figure 12.20: Geographical Clinical Trial Analysis(VC based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.21: Geographical Clinical Trial Analysis(VC based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.22: Geographical Clinical Trial Analysis(Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.23: Geographical Clinical Trial Analysis(Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.24: Geographical Clinical Trial Analysis(SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.25: Geographical Clinical Trial Analysis(SMCC based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.26: Geographical Clinical Trial Analysis(VA based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.27: Geographical Clinical Trial Analysis(VA based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.28: Geographical Clinical Trial Analysis(SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
  • Figure 12.29: Geographical Clinical Trial Analysis(SPDB based Molecules): Distribution by Enrolled Patient Population
  • Figure 12.30: Geographical Clinical Trial Analysis(Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
  • Figure 12.31: Geographical Clinical Trial Analysis(Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
  • Figure 13.1: ADC Therapeutics: Overall Annual Demand
  • Figure 13.2: ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation
  • Figure 13.3: ADC Therapeutics: Overall Annual Commercial Demand
  • Figure 13.4: Annual Commercial Demand: Distribution by Payload Type
  • Figure 13.5: Annual Commercial Demand: Distribution by Linker Type
  • Figure 13.6: Annual Commercial Demand: Distribution by Indication Type
  • Figure 13.7: ADC Therapeutics: Overall Annual Clinical Demand
  • Figure 13.8: Annual Clinical Demand: Distribution by Phase of Development
  • Figure 13.9: Annual Clinical Demand: Distribution by Payload Type
  • Figure 13.10: Annual Clinical Demand: Distribution by Linker Type
  • Figure 13.11: Annual Clinical Demand: Distribution by Indication
  • Figure 13.12: Annual Clinical Demand: Distribution by Region
  • Figure 13.13: ADC Therapeutics: Demand and Supply Analysis, 2018-2030
  • Figure 14.1: Overall ADC Therapeutics Market, 2018-2030(USD Billion)
  • Figure 14.2: ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
  • Figure 14.3: ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
  • Figure 14.4: ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
  • Figure 14.5: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Components of ADC
  • Figure 14.6: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
  • Figure 14.7: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
  • Figure 14.8: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type
  • Figure 14.9: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
  • Figure 14.10: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC
  • Figure 14.11: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
  • Figure 14.12: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
  • Figure 14.13: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type
  • Figure 14.14: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region
  • Figure 15.1: SWOT Analysis: Harvey Ball Analysis
  • Figure 16.1: ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030(USD Billion)

List of Tables:

  • Table 3.1: Commonly used Cytotoxins for ADC Therapeutics
  • Table 3.2: OEL Bands, Safebridge Consultants
  • Table 4.1: ADC Contract Manufacturers: List of Service Providers
  • Table 4.2: ADC Contract Manufacturers: Services Offered
  • Table 4.3: ADC Contract Manufacturers: Details on Manufacturing Facilities
  • Table 4.4: ADC Contract Manufacturers: Details on Scale of Production and Capacity
  • Table 4.5: ADC Contract Manufacturers: Details on Other Services Offered
  • Table 4.6: ADC Contract Manufacturers: List of Antibody Manufacturing Service Providers
  • Table 4.7: ADC Contract Manufacturers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
  • Table 5.1: Abzena: Company Overview and Financial Information
  • Table 5.2: Abzena: ADC Related Offerings
  • Table 5.3: Abzena: Manufacturing Facilities Information
  • Table 5.4: Abzena: Recent Developments
  • Table 5.5: Abzena: Future Outlook
  • Table 5.6: Ajinomoto Althea: Company Overview and Financial Information
  • Table 5.7: Ajinomoto Althea: ADC Related Offerings
  • Table 5.8: Ajinomoto Althea: Manufacturing Facilities Information
  • Table 5.9: Ajinomoto Althea: Recent Developments
  • Table 5.10: Ajinomoto Althea: Future Outlook
  • Table 5.11: BSP Pharmaceuticals: Company Overview
  • Table 5.12: BSP Pharmaceuticals: ADC Related Offerings
  • Table 5.13: BSP Pharmaceuticals: Manufacturing Facilities Information
  • Table 5.14: BSP Pharmaceuticals: Recent Developments
  • Table 5.15: BSP Pharmaceuticals: Future Outlook
  • Table 5.16: CARBOGEN AMCIS: Company Overview and Financial Information
  • Table 5.17: CARBOGEN AMCIS: ADC Related Offerings
  • Table 5.18: CARBOGEN AMCIS: Manufacturing Facilities Information
  • Table 5.19: CARBOGEN AMCIS: Recent Developments
  • Table 5.20: Catalent Pharma Solutions: Company Overview and Financial Information
  • Table 5.21: Catalent Pharma Solutions: ADC Related Offerings
  • Table 5.22: Catalent Pharma Solutions: Manufacturing Facilities Information
  • Table 5.23: Catalent Pharma Solutions: Recent Developments
  • Table 5.24: Catalent Pharma Solutions: Future Outlook
  • Table 5.25: Cerbios-Pharma: Company Overview and Financial Information
  • Table 5.26: Cerbios-Pharma: ADC Related Offerings
  • Table 5.27: Cerbios-Pharma: Manufacturing Facilities Information
  • Table 5.28: Cerbios-Pharma: Recent Developments
  • Table 5.29: Cerbios-Pharma: Future Outlook
  • Table 5.30: Creative Biolabs: Company Overview
  • Table 5.31: Creative Biolabs: ADC Related Offerings
  • Table 5.32: Creative Biolabs: Manufacturing Facilities Information
  • Table 5.33: Creative Biolabs: Recent Developments
  • Table 5.34: Creative Biolabs: Future Outlook
  • Table 5.35: Goodwin Biotechnology: Company Overview and Financial Information
  • Table 5.36: Goodwin Biotechnology: ADC Related Offerings
  • Table 5.37: Goodwin Biotechnology: Manufacturing Facilities Information
  • Table 5.38: Goodwin Biotechnology: Recent Developments
  • Table 5.39: Goodwin Biotechnology: Future Outlook
  • Table 5.40: Levena Biopharma: Company Overview and Financial Information
  • Table 5.41: Levena Biopharma: ADC Related Offerings
  • Table 5.42: Levena Biopharma: Manufacturing Facilities Information
  • Table 5.43: Levena Biopharma: Recent Developments
  • Table 5.44: Levena Biopharma: Future Outlook
  • Table 5.45: Lonza: Company Overview and Financial Information
  • Table 5.46: Lonza: ADC Related Offerings
  • Table 5.47: Lonza: Manufacturing Facilities Information
  • Table 5.48: Lonza: Recent Developments
  • Table 5.49: Lonza: Future Outlook
  • Table 5.50: MabPlex: Company Overview and Financial Information
  • Table 5.51: MabPlex: ADC Related Offerings
  • Table 5.52: MabPlex: Manufacturing Facilities Information
  • Table 5.53: MabPlex: Recent Developments
  • Table 5.54: MabPlex: Future Outlook
  • Table 5.55: Merck(SAFC): Company Overview and Financial Information
  • Table 5.56: Merck(SAFC): ADC Related Offerings
  • Table 5.57: Merck(SAFC): Information on Manufacturing Facilities
  • Table 5.58: Merck(SAFC): Recent Developments
  • Table 5.59: Merck(SAFC): Future Outlook
  • Table 5.60: Novasep: Company Overview and Financial Information
  • Table 5.61: Novasep: ADC Related Offerings
  • Table 5.62: Novasep: Manufacturing Facilities Information
  • Table 5.63: Novasep: Recent Developments
  • Table 5.64: Novasep: Future Outlook
  • Table 5.65: Pierre Fabre: Company Overview and Financial Information
  • Table 5.66: Pierre Fabre: ADC Related Offerings
  • Table 5.67: Pierre Fabre: Manufacturing Facilities Information
  • Table 5.68: Pierre Fabre: Recent Developments
  • Table 5.69: Pierre Fabre: Future Outlook
  • Table 5.70: Piramal Pharma Solutions: Company Overview and Financial Information
  • Table 5.71: Piramal Pharma Solutions: ADC Related Offerings
  • Table 5.72: Piramal Pharma Solutions: Manufacturing Facilities Information
  • Table 5.73: Piramal Pharma Solutions: Recent Developments
  • Table 5.74: Piramal Pharma Solutions: Future Outlook
  • Table 5.75: Syngene: Company Overview and Financial Information
  • Table 5.76: Syngene: ADC Related Offerings
  • Table 5.77: Syngene: Information on Manufacturing Facilities
  • Table 5.78: Syngene: Recent Developments
  • Table 5.79: Syngene: Future Outlook
  • Table 5.80: WuXi Biologics: Company Overview and Financial Information
  • Table 5.81: WuXi Biologics: ADC Related Offerings
  • Table 5.82: WuXi Biologics: Manufacturing Facilities Information
  • Table 5.83: WuXi Biologics: Recent Developments
  • Table 5.84: WuXi Biologics: Future Outlook
  • Table 6.1: Company Competitiveness Analysis: Shortlisted Players
  • Table 6.2: Company Competitiveness Analysis: Spiderweb Parameters for Shortlisted Players
  • Table 7.1: ADC Contract Manufacturing: Recent Developments
  • Table 8.1: ADC Contract Manufacturing: Partnerships and Collaborations, 2012-2018
  • Table 8.2: ADC Contract Manufacturing Partnerships: Most Active Players
  • Table 9.1: ADC Manufacturing Installed Global Capacity: Average Capacity in Grams(Sample Data Set)
  • Table 9.2: ADC Manufacturing Installed Global Capacity in Grams: Total Capacity by Size of Manufacturers
  • Table 10.1: ADC Therapeutics: Clinical Pipeline
  • Table 10.2: ADC Therapeutics: Clinical Pipeline(Information on Linkers and Payloads)
  • Table 10.3: ADC Therapeutics: Preclinical / Discovery Pipeline
  • Table 11.1: Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
  • Table 11.2: Second Generation ADC Technologies: Unnatural Amino Acid Engineering
  • Table 11.3: Second Generation ADC Technologies: Amino-terminal Engineered Serine
  • Table 11.4: Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 11.5: Third Generation ADC Technologies: Glycan Remodeling Approaches
  • Table 11.6: Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 11.7: Third Generation ADC Technologies: Cysteine Rebridging
  • Table 11.8: Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
  • Table 12.1: Geographical Clinical Trial Analysis(Auristatin Based Molecules): Duration of Trials
  • Table 12.2: Geographical Clinical Trial Analysis(Maytansinoid Based Molecules): Duration of Trials
  • Table 12.3: Geographical Clinical Trial Analysis(Calicheamicin Based Molecules): Duration of Trials
  • Table 12.4: Geographical Clinical Trial Analysis(PBDs Based Molecules): Duration of Trials
  • Table 12.5: Geographical Clinical Trial Analysis(Duocarmycin Based Molecules): Duration of Trials
  • Table 12.6: Geographical Clinical Trial Analysis(DXd Based Molecules): Duration of Trials
  • Table 12.7: Geographical Clinical Trial Analysis(Other Types of Payload based Molecules): Duration of the Trials
  • Table 12.8: Geographical Clinical Trial Analysis(VC based Molecules): Duration of the Trials
  • Table 12.9: Geographical Clinical Trial Analysis(Hydrazone Linker Based Molecules): Duration of Trials
  • Table 12.10: Geographical Clinical Trial Analysis(SMCC Based Molecules): Duration of Trials
  • Table 12.11: Geographical Clinical Trial Analysis(Auristatin Based Molecules): Duration of Trials
  • Table 12.12: Geographical Clinical Trial Analysis(Auristatin Based Molecules): Duration of Trials
  • Table 12.13: Other Types of Linkers based ADC Therapeutics: Duration of the Trials
  • Table 14.1: Late Stage ADCs: Development Status
  • Table 14.2: ADC Therapeutics: Outsourcing Activity for Late Stage Molecules
  • Table 18.1: ADC Contract Manufacturers: Distribution by Location of Headquarters
  • Table 18.2: ADC Contract Manufacturers: Distribution by Year of Establishment
  • Table 18.3: ADC Contract Manufacturers: Distribution by Company Size
  • Table 18.4: ADC Contract Manufacturers: Distribution by Services Offered
  • Table 18.5: ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
  • Table 18.6: ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Table 18.7: ADC Contract Manufacturers: Distribution by Scale of Operation
  • Table 18.8: ADC Contract Manufacturers: Distribution based on Other Services Offered
  • Table 18.9: ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
  • Table 18.10: ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
  • Table 18.11: ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
  • Table 18.12: ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
  • Table 18.13: ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
  • Table 18.14: ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
  • Table 18.15: ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
  • Table 18.16: ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
  • Table 18.17: ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
  • Table 18.18: ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
  • Table 18.19: ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
  • Table 18.20: ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
  • Table 18.21: ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
  • Table 18.22: Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
  • Table 18.23: Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
  • Table 18.24: Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
  • Table 18.25: Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities(by Country)
  • Table 18.26: Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities(by Continent)
  • Table 18.27: ADCs Clinical Pipeline: Distribution by Phase of Development
  • Table 18.28: ADCs Clinical Pipeline: Distribution by Indication
  • Table 18.29: ADCs Clinical Pipeline: Distribution by Type of Linker
  • Table 18.30: ADCs Clinical Pipeline: Distribution by Type of Warhead
  • Table 18.31: ADCs Clinical Pipeline: Distribution by Technology Providers
  • Table 18.32: ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
  • Table 18.33: ADC Therapeutics: Year-wise Trend of Clinical Trials
  • Table 18.34: Geographical Clinical Trial Analysis: Distribution by Number of Trials
  • Table 18.35: Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
  • Table 18.36: Geographical Clinical Trial Analysis: Distribution by Payload Type
  • Table 18.37: Geographical Clinical Trial Analysis(Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.38: Geographical Clinical Trial Analysis(Auristatin based Molecules): Distribution by Enrolled Patient Population
  • Table 18.39: Geographical Clinical Trial Analysis(Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.40: Geographical Clinical Trial Analysis(Maytansinoid based Molecules): Distribution by Enrolled Patient Population
  • Table 18.41: Geographical Clinical Trial Analysis(Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.42: Geographical Clinical Trial Analysis(Calicheamicin based Molecules): Distribution by Enrolled Patient Population
  • Table 18.43: Geographical Clinical Trial Analysis(PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.44: Geographical Clinical Trial Analysis(PBDs based Molecules): Distribution by Enrolled Patient Population
  • Table 18.45: Geographical Clinical Trial Analysis(Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.46: Geographical Clinical Trial Analysis(Duocarmycin based Molecules): Distribution by Enrolled Patient Population
  • Table 18.47: Geographical Clinical Trial Analysis(DXd based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.48: Geographical Clinical Trial Analysis(DXd based Molecules): Distribution by Enrolled Patient Population
  • Table 18.49: Geographical Clinical Trial Analysis(Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
  • Table 18.50: Geographical Clinical Trial Analysis(Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
  • Table 18.51: ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
  • Table 18.52: Geographical Clinical Trial Analysis(VC based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.53: Geographical Clinical Trial Analysis(VC based Molecules): Distribution by Enrolled Patient Population
  • Table 18.54: Geographical Clinical Trial Analysis(Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.55: Geographical Clinical Trial Analysis(Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
  • Table 18.56: Geographical Clinical Trial Analysis(SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.57: Geographical Clinical Trial Analysis(SMCC based Molecules): Distribution by Enrolled Patient Population
  • Table 18.58: Geographical Clinical Trial Analysis(VA based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.59: Geographical Clinical Trial Analysis(VA based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.60: Geographical Clinical Trial Analysis(SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
  • Table 18.61: Geographical Clinical Trial Analysis(SPDB based Molecules): Distribution by Enrolled Patient Population
  • Table 18.62: Geographical Clinical Trial Analysis(Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
  • Table 18.63: Geographical Clinical Trial Analysis(Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
  • Table 18.64: ADC Therapeutics: Overall Annual Demand
  • Table 18.65: ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation
  • Table 18.66: ADC Therapeutics: Overall Annual Commercial Demand
  • Table 18.67: Annual Commercial Demand: Distribution by Payload Type
  • Table 18.68: Annual Commercial Demand: Distribution by Linker Type
  • Table 18.69: Annual Commercial Demand: Distribution by Indication Type
  • Table 18.70: ADC Therapeutics: Overall Annual Clinical Demand
  • Table 18.71: Annual Clinical Demand: Distribution by Phase of Development
  • Table 18.72: Annual Clinical Demand: Distribution by Payload Type
  • Table 18.73: Annual Clinical Demand: Distribution by Linker Type
  • Table 18.74: Annual Clinical Demand: Distribution by Indication
  • Table 18.75: Annual Clinical Demand: Distribution by Region
  • Table 18.76: Overall ADC Therapeutics Market: Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 18.77: ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
  • Table 18.78: ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type, Conservative, Base and Optimistic Scenarios
  • Table 18.79: ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios
  • Table 18.80: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type, Conservative, Base and Optimistic Scenarios
  • Table 18.81: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios
  • Table 18.82: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios
  • Table 18.83: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Indication Type, Conservative, Base and Optimistic Scenarios
  • Table 18.84: ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region, Conservative, Base and Optimistic Scenarios
  • Table 18.85: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC, Conservative, Base and Optimistic Scenarios
  • Table 18.86: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios
  • Table 18.87: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios
  • Table 18.88: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Indication Type, Conservative, Base and Optimistic Scenarios
  • Table 18.89: ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region, Conservative, Base and Optimistic Scenarios
  • Table 18.90: SWOT Analysis: Harvey Ball Analysis
  • Table 18.91: ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030(USD Billion)

Listed Companies:

The following companies and organizations have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. AB Sciex
  • 3. AbbVie
  • 4. AbGenomics
  • 5. ABL Bio
  • 6. Abzena
  • 7. ACES Pharma
  • 8. Adar Biotech
  • 9. ADC Biotechnology
  • 10. ADC Therapeutics
  • 11. Advanced BioScience Laboratories
  • 12. Aesica Pharmaceuticals
  • 13. Affinity Life Sciences
  • 14. Agensys
  • 15. Agno Pharma
  • 16. Ajinomoto Althea
  • 17. Alcami
  • 18. Aldevron
  • 19. Alkermes
  • 20. Allozyne
  • 21. Almac
  • 22. Alpha Cancer Technologies
  • 23. Alphora Research
  • 24. Alteogen
  • 25. Amatsigroup
  • 26. Ambrx
  • 27. Amgen
  • 28. AMPAC Fine Chemicals
  • 29. AMRI
  • 30. Angiex
  • 31. Anogen
  • 32. APO-T
  • 33. Aptuit
  • 34. AqueaTether Therapeutics
  • 35. Arabio
  • 36. Arch Pharmalabs
  • 37. Asana BioSciences
  • 38. Ash Stevens
  • 39. Aspyrian Therapeutics
  • 40. Astellas Pharma
  • 41. AstraZeneca
  • 42. Asymchem
  • 43. AURA Biotechnologies
  • 44. AutekBio
  • 45. Avanthera
  • 46. Avid Bioservices
  • 47. Batavia Biosciences
  • 48. Baxter BioPharma Solutions
  • 49. Bayer HealthCare
  • 50. BerGenBio
  • 51. Bharat Serums and Vaccines
  • 52. BIBITEC
  • 53. BINEX
  • 54. BioAgilytix
  • 55. BioConnection
  • 56. Biomatik
  • 57. BioMed Valley Discoveries
  • 58. Biosynergy
  • 59. Bio-Synthesis
  • 60. BioTechLogic
  • 61. BioTechnique
  • 62. Biotechpharma
  • 63. Biotecnol
  • 64. Biotest
  • 65. BioVectra
  • 66. Biovian
  • 67. BlinkBio
  • 68. Bliss Biopharmaceutical
  • 69. Boehringer Ingelheim BioXcellence
  • 70. Bristol-Myers Squibb
  • 71. Bryllan
  • 72. BSP Pharmaceuticals
  • 73. Cambrex
  • 74. Cambridge Major Laboratories
  • 75. Capsugel
  • 76. CARBOGEN AMCIS
  • 77. Catalent Pharma Solutions
  • 78. Cedarburg Pharmaceuticals
  • 79. Celgene
  • 80. Cell Culture Company
  • 81. Cell Essentials
  • 82. Cellerant Therapeutics
  • 83. CellMosaic
  • 84. Celltrion
  • 85. Celon Laboratories
  • 86. Celonic
  • 87. Centrose
  • 88. Cerbios-Pharma
  • 89. Charles River Laboratories
  • 90. ChemCon
  • 91. ChemPartner
  • 92. ChemSun Pharmaceutical
  • 93. Chiome Bioscience
  • 94. Chugai Pharmaceutical
  • 95. CinnaGen
  • 96. CMC Biologics
  • 97. Cobra Biologics
  • 98. Coldstream Laboratories
  • 99. Compugen
  • 100. Concortis Biotherapeutics
  • 101. Cook Pharmica
  • 102. CordenPharma
  • 103. Creative Biolabs
  • 104. Crystal Pharma
  • 105. Custom Pharma Services
  • 106. CytomX Therapeutics
  • 107. Cytovance Biologics
  • 108. Daiichi Sankyo
  • 109. Dalton Pharma Services
  • 110. Debiopharm
  • 111. DM Bio
  • 112. Dorizoe Lifesciences
  • 113. Dottikon Exclusive Synthesis
  • 114. DSM Pharmaceuticals
  • 115. EirGen Pharma
  • 116. EirGenix
  • 117. Eli Lilly
  • 118. Emergent BioSolutions
  • 119. Esperance Pharmaceuticals
  • 120. ETH Zurich
  • 121. EuBiologics
  • 122. Evonik
  • 123. Excella
  • 124. Farmabios
  • 125. FineTech Pharmaceuticals
  • 126. Formation Biologics
  • 127. Formex
  • 128. Formosa Laboratories
  • 129. For-Robin
  • 130. Fortis Therapeutics
  • 131. FOSUN Pharma
  • 132. FUJIFILM Diosynth Biotechnologies
  • 133. Fusion Antibodies
  • 134. Gala Biotech
  • 135. GE Healthcare
  • 136. GEA Pharma Systems
  • 137. Genentech
  • 138. Genmab
  • 139. Genzyme
  • 140. Glenmark Pharmaceuticals
  • 141. Glycotope Biotechnology
  • 142. Glythera
  • 143. Goodwin Biotechnology
  • 144. GP Pharm
  • 145. Grand River Aseptic Manufacturing
  • 146. Green Cross
  • 147. Groningen Research Institute of Pharmacy
  • 148. GSK
  • 149. GTP Technology
  • 150. HALIX
  • 151. Halozyme
  • 152. Hangzhou DAC Biotech
  • 153. Haupt Pharma
  • 154. Heidelberg Pharma
  • 155. Helsinn Advanced Synthesis
  • 156. Heraeus Deutschland
  • 157. Hetero
  • 158. Hong Kong Institute of Biotechnology
  • 159. ICROM
  • 160. Idifarma
  • 161. IDT Australia
  • 162. IDT Biologika
  • 163. Igenica Biotherapeutics
  • 164. ImmunoGen
  • 165. Immunomedics
  • 166. Indena
  • 167. Innate Pharma
  • 168. Inno Biologics
  • 169. Innovation Center for Immune Therapy, Tsinghua University
  • 170. Intas Pharmaceuticals
  • 171. Integrity Bio
  • 172. Intellect Neurosciences
  • 173. IRIX Pharmaceuticals
  • 174. JHL Biotech
  • 175. Johns Hopkins University
  • 176. Johnson Matthey
  • 177. Kamat Pharmatech
  • 178. KBI Biopharma
  • 179. Kemwell Biopharma
  • 180. Kyongbo Pharmaceutical
  • 181. Kyowa Hakko Kirin
  • 182. Labochim
  • 183. LAMPIRE Biological Laboratories
  • 184. LegoChem Biosciences
  • 185. Leica Biosystems
  • 186. Levena Biopharma
  • 187. LFB Biomanufacturing
  • 188. LinXis
  • 189. Lonza
  • 190. MAB Discovery
  • 191. MabPlex
  • 192. MabVax Therapeutics
  • 193. MacroGenics
  • 194. Maine Biotechnology Services
  • 195. MassBiologics
  • 196. Medichem
  • 197. MedImmune
  • 198. Meditope Biosciences
  • 199. Medix Biochemica
  • 200. Menarini Group
  • 201. Merck (SAFC)
  • 202. Meridian Life Science
  • 203. Merrimack Pharmaceuticals
  • 204. Mersana Therapeutics
  • 205. Metrics Contract Services
  • 206. Millennium Pharmaceuticals
  • 207. MINAKEM High Potent
  • 208. Mitsubishi Tanabe Pharma
  • 209. Molecular and Cellular Therapeutics, University of Minnesota
  • 210. Morphotek
  • 211. MuseChem
  • 212. Mycenax Biotech
  • 213. NanoValent Pharmaceuticals
  • 214. National Cancer Institute
  • 215. National Research Council Canada
  • 216. NBE Therapeutics
  • 217. NerPharma
  • 218. Nitto Avecia Pharma Services
  • 219. Nordic Nanovector
  • 220. Laboratorios Normon
  • 221. Nova Laboratories
  • 222. Novartis
  • 223. Novasep
  • 224. OBI Pharma
  • 225. OctoPlus
  • 226. Olon
  • 227. OmniChem
  • 228. Oncotec Pharma Produktion
  • 229. Hospira One2One
  • 230. OsoBio
  • 231. Oxford BioTherapeutics
  • 232. Panacea Biotec
  • 233. Paragon Bioservices
  • 234. Particle Sciences
  • 235. Patheon
  • 236. Penn Pharma
  • 237. Pfanstiehl
  • 238. Pfizer
  • 239. Pharmaceutics International
  • 240. PharmaMar
  • 241. Pharmatek
  • 242. Pharmedartis
  • 243. Philochem
  • 244. Philogen
  • 245. Pierre Fabre
  • 246. Piramal Pharma Solutions
  • 247. Polymun Scientific
  • 248. PrasFarma
  • 249. Praxis Pharmaceutical
  • 250. Precision Antibody
  • 251. PREMAS Biotech
  • 252. ProBioGen
  • 253. Procos
  • 254. ProJect Pharmaceutics
  • 255. ProMab Biotechnologies
  • 256. PX'Therapeutics
  • 257. Quotient Sciences
  • 258. Recipharm
  • 259. Redwood Bioscience
  • 260. Regeneron Pharmaceuticals
  • 261. Regis Technologies
  • 262. Reliance Life Sciences
  • 263. RemeGen
  • 264. Rentschler Biopharma
  • 265. Research Corporation Technologies
  • 266. Richter-Helm BioLogics
  • 267. Roche
  • 268. Rottendorf Pharma
  • 269. Saltigo
  • 270. Samsung Medical Center
  • 271. Sandoz
  • 272. Sanofi
  • 273. Sartorius Stedim Biotech
  • 274. ScinoPharm
  • 275. Seasun Biomaterials
  • 276. Seattle Genetics
  • 277. Shenogen
  • 278. Siegfried
  • 279. Sorrento Therapeutics
  • 280. Spirogen
  • 281. STA Pharmaceutical
  • 282. Stason Pharmaceuticals
  • 283. Stemcentrx
  • 284. Sutro Biopharma
  • 285. Symbiosis Pharmaceutical Services
  • 286. Symphogen
  • 287. Synaffix
  • 288. Syndivia
  • 289. Syngene
  • 290. Syntagon
  • 291. Synthon
  • 292. Synthorx
  • 293. Takara Bio
  • 294. Takeda Oncology
  • 295. TAPI
  • 296. TBD-Biodiscovery
  • 297. Telix Pharmaceuticals
  • 298. The Chemistry Research Solution
  • 299. The Scripps Research Institute
  • 300. Theranyx
  • 301. Therapure Biopharma
  • 302. Thermo Fisher Scientific
  • 303. Toyobo Biologics
  • 304. Transporin
  • 305. TranXenoGen
  • 306. Triphase Accelerator
  • 307. Tube Pharma
  • 308. Uman Pharma
  • 309. University of Bonn
  • 310. University of California
  • 311. University of Georgia
  • 312. UPM Pharmaceuticals
  • 313. Uquifa
  • 314. Vaccinex
  • 315. Vetter Pharma
  • 316. Vista Biologicals
  • 317. Visterra
  • 318. VUAB Pharma
  • 319. Waisman Biomanufacturing
  • 320. Weill Cornell Medicine
  • 321. Wolfe Laboratories
  • 322. WuXi Biologics
  • 323. Xintela
  • 324. Yale School of Medicine
  • 325. Zymeworks
Back to Top